TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
|
|
- Mark Kelly
- 6 years ago
- Views:
Transcription
1 TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
2 DISCLOSURES Honoraria: Amgen, Merck, Shire Consulting : AbbVie, Amgen, Merck, Radius, Sanofi Research support: Shire
3 FDA-APPROVED MEDICATIONS INDICATIONS Postmenopausal Osteoporosis Glucocorticoid-induced Osteoporosis Men Drug Prevention Treatment Prevention Treatment Estrogen Calcitonin (Miacalcin, Fortical ) Raloxifene (Evista ) Ibandronate (Boniva ) Alendronate (Fosamax ) Risedronate (Actonel ) Risedronate (Atelvia ) Zoledronate (Reclast ) Denosumab (Prolia ) Teriparatide (Forteo )
4 FDA-APPROVED MEDICATIONS EVIDENCE FOR FRACTURE REDUCTION Drug Vertebral Fracture Nonvertebral Fracture Hip Fracture Calcitonin (Miacalcin, Fortical ) No effect demonstrated No effect demonstrated Raloxifene (Evista ) No effect demonstrated No effect demonstrated Ibandronate (Boniva ) No effect demonstrated No effect demonstrated Alendronate (Fosamax ) Risedronate (Actonel, Atelvia ) Zoledronic acid (Reclast ) Denosumab (Prolia ) Teriparatide (Forteo ) No effect demonstrated Evidence for effect but not an FDA-approved indication
5 ACTION OF BISPHOSPHONATES ON OSTEOCLASTS Bind to bone mineral BP Bone BP BP BP Concentrate at sites of bone resorption BP Bone BP BP BP BP BP BP BP Release and intracellular uptake during resorption BP BP BP Bone Loss of resorptive function BP = bisphosphonates Courtesy of Mike Rogers (2005)
6 BISPHOSPHONATES AVAILABLE IN THE US Daily Weekly Monthly IV Alendronate* (Fosamax ) Risedronate (Actonel, Atelvia ) Ibandronate (Boniva ) Zoledronate (Reclast 5 & 10 mg 35 & 70 mg 5 mg 35 mg 150 mg 2.5 mg 150 mg 3 mg q 3 mo 5 mg/yr *Alendronate available as alendronate alone (brand or generic) or 70 mg with vitamin D 2800 or 5600 IU (brand only) Atelvia should be taken once weekly, immediately after breakfast
7 BISPHOSPHONATES SIDE EFFECTS / SAFETY CONCERNS Short-term side effects Hypocalcemia Esophageal irritation (oral) Acute phase response (IV and high-dose oral) Acute renal damage (IV) Musculoskeletal pain* Long-term safety concerns Osteonecrosis of the jaw* Atypical femur fractures* *Reports from post-marketing surveillance
8
9 SIDE BENEFITS OF BISPHOSPHONATE THERAPY Decreased risk of breast cancer 1-5 Decreased risk of colorectal cancer 6 Decreased risk of stroke 7 Decreased risk of MI 8 Reduced risk of gastric cancer 9 Decreased overall mortality10, Chlebowski RT et al. J Clin Oncol 2010; 28: Dreyfuss JH. CA Cancer 2010; 60: Newcomb PA et al. Br J Cancer 2010; 102: Rennert G et al. J Clin Oncol 2010; 28: Vestergaard P et al. Calcif Tissue Int 2011; 88: Rennert G, et al. J Clin Oncol 2011; 29: Kang JH et al. Osteoporos Int 2012; [Epub ahead of print] 8. Wolfe F et al, J Bone Miner Res 2013; 28: Abrahamsen B et al. J Bone Miner Res 2012;27: Center JR et al. J Clin Endocrinol Metab 2011; 96: Sambrook PN et al. Osteoporos Int 2011; 22:2551.
10 HOW LONG SHOULD TREATMENT LAST? A question unique to bisphosphonates; no other agent used to treat osteoporosis (or other chronic disease) has a cumulative effect or potential for residual benefit Bisphosphonates have a long residence time in bone Does long-term treatment create safety concerns that limit the duration of treatment? Given the long retention in bone, with release and possibly recycling of drug, does cumulative exposure lead to a reservoir in bone, so that after therapy is stopped, sufficient drug will be released to exert a continuing benefit?
11 OSTEONECROSIS OF THE JAW Exposed necrotic bone in the maxillo-facial region, not healing after 6-8 weeks of appropriate management, often at the site of a dental extraction or other invasive dental procedure or in patients with poorly fitting dentures Over 90% of reported cases have been in cancer patients receiving BP doses 10x higher than used to treat osteoporosis Estimated incidence in osteoporosis: 1:10,000-1:100,000 Current guidelines from the American Dental Assn. (2011) emphasize the health consequences of osteoporosis, the benefits of bisphosphonate treatment and the low risk of ONJ in osteoporosis patients receiving bisphosphonate therapy Woo S-B et al. Ann Intern Med 2006;144: Khosla S et al. J Bone Miner Res 2008;23: Hellstein JW et al. JADA 2011:142:
12 FEMUR FRACTURES TYPICAL FEMUR FRACTURES No warning symptoms Caused by a fall Unilateral Proximal Acute angle (femoral neck, intertrochanteric) May be comminuted *Major features **Required for diagnosis ATYPICAL FEMUR FRACTURES Prodromal thigh or groin pain Little or no trauma* ~30% bilateral Subtrochanteric location** Transverse/oblique, medial spike* Little or no comminution* Begin as a localized periosteal reaction of the lateral cortex* Thick cortices Delayed healing ASBMR Task Force Shane E et al, JBMR 2010;25: Shane E et al, JBMR 2014;29:1-23
13 2014 UPDATE: ASBMR TASK FORCE ON ATYPICAL FEMUR FRACTURES Location: below lesser trochanter, above supracondylar flare Major Features (four of five) Trauma: little or none Direction: lateral transverse, may be oblique on the medial side Comminution: little or none Complete fractures: may have a medial spike; incomplete fractures involve only the lateral cortex Localized periosteal reaction/thickening of the lateral cortex Minor features (none required) Generalized increase in cortical thickness of the shaft Prodromal symptoms such as dull aching pain in groin or thigh Bilateral incomplete or complete fractures and symptoms Delayed fracture healing Shane E et al, JBMR 2014;29:1-23
14 SUBTROCHANTERIC FEMUR FRACTURE This patient had not been on a bisphosphonate or any other treatment for osteoporosis
15 ATYPICAL FRACTURES OF THE FEMUR Watts NB and Diab D, J Clin Endocrinol Metab 2010;95:
16 ATYPICAL FEMORAL FRACTURES 1.5 million women 55 and older with fx from any cause 12,777 (0.9%) had femur fractures Schilcher J et al, N Engl J Med 2011;364:
17 ATYPICAL FEMORAL FRACTURES 10.6% of all femur fractures were in the shaft Schilcher J et al, N Engl J Med 2011;364:
18 ATYPICAL FEMORAL FRACTURES 10.6% of all femur fractures were in the shaft 59 were atypical fractures 0.46% of all femur fractures 4.4% of all shaft fractures Schilcher J et al, N Engl J Med 2011;364:
19 ATYPICAL FEMORAL FRACTURES 10.6% of all femur fractures were in the shaft Atypical fractures accounted for 0.46% of all femur fractures and 4.4% of all shaft fractures. Absolute risk increase: 5 cases per 10,000 pt years Schilcher J et al, N Engl J Med 2011;364:
20 ATYPICAL FEMORAL FRACTURES Only 11% were using bisphosphonates! Assume 35% risk reduction 4,000 fractures could have been prevented 10.6% of all femur fractures were in the shaft Atypical fractures accounted for 0.46% of all femur fractures and 4.4% of all shaft fractures. Absolute risk increase: 5 cases per 10,000 pt years Schilcher J et al, N Engl J Med 2011;364:
21 LONG-TERM EXPERIENCE WITH ALENDRONATE FIT LONG-TERM EXTENSION (FLEX) STUDY Patients who received ~5 years of alendronate in the Fracture Intervention Trial agreed to a second 5-yr study Re-randomized to stay on alendronate (n=672) or changed to placebo (n=437) For those who had 10 years of alendronate compared with stopping after 5 years Overall, clinical vertebral fractures were reduced 55% In women with T-scores -2.5 or below at the start of FLEX, nonvertebral fractures were reduced by 50% Black DM et al, JAMA 2006;296: Schwartz AV et al. J Bone Miner Res 2010;25:
22 CLINICAL VERTEBRAL FRACTURES IN THE FLEX STUDY Cumulative incidence of fractures (%) ALN 5 years Placebo 5 years Alendronate 10 years RR 55% P= % 2.5% Years Since FIT ALN/PLB ALN/ALN Black DM et al, JAMA 2006;296:
23 CLINICAL VERTEBRAL FRACTURES IN THE FLEX STUDY Cumulative incidence of fractures (%) ALN 5 years Placebo 5 years Alendronate 10 years RR 55% P= % 2.5% Years Since FIT ALN/PLB ALN/ALN Black DM et al, JAMA 2006;296:
24 ALGORITHM FOR MANAGEMENT OF POSTMENOPAUSAL WOMEN ON LONG TERM BISPHOSPHONATE THERAPY Adler R. et al, J Bone Miner Res 2016;31:16-35
25 WHEN SHOULD THE HOLIDAY END? YOU ARE ENTERING A DATA-FREE ZONE
26 WHEN SHOULD THE HOLIDAY END? Arbitrary? Longer for drugs with highest skeletal affinity (zoledronic acid), shorter for drugs with lowest skeletal affinity (risedronate) Longer for lower risk patients, shorter for those at high risk Bone turnover markers? Which marker? How high? BMD? Decrease more than the least significant change (LSC) Watts NB and Diab D, J Clin Endocrinol Metab 2010;95:
27 DENOSUMAB (PROLIA ) Human monoclonal antibody to RANKL; blocks binding to RANKL, decreases osteoclast differentiation, function and survival Reduces the risk of spine, hip and other nonvertebral fractures compared with placebo For treatment of osteoporosis, the dose is 60 mg SQ every 6 months Contraindicated in patients with hypocalcemia Can be used without dose adjustment in patients with decreased kidney function Bekker PJ et al. J Bone Miner Res. 2004;19: Boyle WJ et al. Nature. 2003;423: Peterson, et. al. J. Bone Miner. Res. 2003; 18(suppl. 2): S166. Abstract SA393 and poster Cummings SR et al, N Engl J Med 2009;361: Prolia Package Insert
28 DENOSUMAB FREEDOM TRIAL 3-YEAR FRACTURE RESULTS Subjects with New Fractures (%) ,808 postmenopausal women with osteoporosis 68% 20% Placebo Denosumab 40% Vertebral Non-Vert Hip Cummings SR et al, N Engl J Med 2009;361:
29 BMD CHANGE AFTER STOPPING DENOSUMAB 12 Lumbar Spine BMD All discontinued % Change (LS mean ± SE) All discontinued at 36 months Subjects who rec d 30 mg q 3 mos were given 60 mg q 6 mos starting at Month 36 Months Miller PD et al Bone 2008;43:
30 Management of osteoporosis is a longterm proposition, similar to treatment of hypertension or hypercholesterolemia
31 Prepared by Nelson Watts MD YEAR BMD CHANGE WITH DENOSUMAB Percentage Change from Baseline Lumbar spine Total hip Bone HG et al, ASBMR 2015
32 FRACTURES AFER EIGHT YEARS OF DENOSUMAB Papapoulos S et al, Osteoporos Int 2015;epub ahead of print
33 Placebo Years 1-3 D mab Years 4-6 Crossover Group D mab Years 1-3 D mab Years 4-6 Long-term Group Watts NB et al ASBMR 2015
34 LONG-TERM SAFETY WITH D MAB Watts NB et al ASBMR 2015
35 LONG-TERM SAFETY WITH D MAB Watts NB et al ASBMR 2015
36 NONSKELETAL EXPRESSION OF RANKL RANKL Bone marrow stromal cells Activated T cells B cells Fibroblasts Endothelial cells Chrondrocytes Mammary epithelial cells RANK Dendritic cells Chondrocytes Endothelial cells Fibroblasts Macrophages Other cells OPG Bone marrow stromal cells Fibroblasts Endothelial cells Lymphoid cells Smooth muscle cells Mature B cells NOT thymocytes, peripheral blood lymphocytes Kearns AE et al. Endocrine Reviews 2008;29:
37 WHAT ABOUT CONCOMITANT USE OF D MAB AND ANTI-TNF AGENTS? Source: Medicare database Subjects: RA patients, all receiving biologic agents, getting either ZOL (n=4,460) or dmab (n=1,354) Findings: no difference in rates of hospitalization for infection (matched analysis) and similar to reported rates in older patients not receiving dmab or ZOL Dmab 9.4 ( ) cases per 100 patient years ZOL 11.7 ( ) cases per 100 patient years Curtis JR et al, Arthritis & Rheumatol 2015;67:
38 SEQUENTIAL OR CONCOMITANT COMBINATIONS DENOSUMAB AND TERIPARATIDE ` Years 1-2 Years 3-4 Combination Denosumab Teriparatide Denosumab Denosumab Teriparatide Leder B et al Lancet 2015;336:1147
39 SEQUENTIAL OR CONCOMITANT COMBINATIONS DENOSUMAB AND TERIPARATIDE ` Years 1-2 Years 3-4 Combination Denosumab Teriparatide Denosumab Denosumab Teriparatide Leder B et al Lancet 2015;336:1147
40 SEQUENTIAL OR CONCOMITANT COMBINATIONS DENOSUMAB AND TERIPARATIDE Years 1-2 Years 3-4 Combination Denosumab Teriparatide Denosumab Denosumab Teriparatide Leder B et al Lancet 2015;336:1147
41 TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Treatment of osteoporosis is a long-term proposition, similar to management of other chronic silent diseases (hypertension, hyperlipidemia and diabetes) Because bisphosphonates accumulate in bone, it is possible to stop administration for a time with continued therapeutic effect during a drug holiday Lower risk patients, 3 years of IV or 5 years of oral Higher risk, 6 years of IV or 10 years of oral No holiday for denosumab or other agent but, depending on drug and situation, changes between agents may be OK.
42 Questions or comments? WILL YOUR BONES LAST AS LONG AS YOU DO?
9/9/2015 OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY DISCLOSURES
OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Stock options/holdings,
More informationTREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE. Nelson B. Watts, MD
TREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO Honoraria: Amgen, Radius, Shire Consulting
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationDisclosure. Objectives. Osteoporosis. Major Public Health Concern Will I end up like my mother?
Everything a Pharmacist Needs to Know About Osteoporosis New Mexico Pharmacists Association Mid-Winter Meeting January 27-28, 2018 Albuquerque, NM Consulting Amgen, Radius Speaking Radius Disclosure E.
More informationOsteoporosis Management
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
More informationOsteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017
Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017 Introduction A fracture due to OP occurs every 3 seconds around the world. 1
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationDisclosures D. Black. Bisphosphonates: Background, Efficacy and Recent Controversies. Page 1. Research Funding: Novartis, Merck
Bisphosphonates: Background, Efficacy and Recent Controversies Disclosures D. Black Research Funding: Novartis, Merck Dennis M. Black, PhD Consulting: Amgen, Lilly, Zosano, Nycomed Dept. of Epidemiology
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationBalancing the Risks and Benefits of Osteoporosis Treatment: part I: 3 to 5 years treatment
Balancing the Risks and Benefits of Osteoporosis Treatment: part I: 3 to 5 years treatment Dennis M. Black, PhD Department of Epidemiology and Biostatistics, UCSF Financial Disclosures (past 3 years) -Consulting
More informationRefracture Prevention The Role of Primary Care
MonashHealth Refracture Prevention The Role of Primary Care Professor Peter R Ebeling AO MBBS MD FRACP Head, Department of Medicine School for Clinical Sciences Monash Health Translation Precinct Monash
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationTherapeutic Updates in the Prevention and Treatment of Osteoporosis
Therapeutic Updates in the Prevention and Treatment of Osteoporosis 2013 Fall Managed Care Forum Las Vegas November 15, 2013 Steven T Harris MD FACP Clinical Professor of Medicine University of California,
More informationRheumatology. keeping Joints in Motion. Treating and Preventing Fractures
Rheumatology keeping Joints in Motion Treating and Preventing Fractures Robin K. Dore, MD Clinical Professor of Medicine David Geffen School of Medicine at UCLA, Los Angeles CA Private practice, Tustin
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationDrugs Approved for Prevention and Treatment of Postmenopausal Osteoporosis
Other Treatments of Osteoporosis- Who Should Get Bisphosphonates David Slovik, M.D. Endocrine Unit Newton-Wellesley Hospital Massachusetts General Hospital Harvard Medical School Massachusetts Medical
More informationCalcium, Vitamin D and Bisphosphonates: Disclosures. Benefits, Risks and Drug Holiday. Calcium YES or NO? Calcium Bad News!!
Calcium, Vitamin D and Bisphosphonates: Benefits, Risks and Drug Holiday Disclosures I am disclosing financial relationships as follows: Global Advisory Boards: Amgen, Lilly, Merck, Novartis Research grants:
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More informationTask Force Co-Chairs. Members
Managing Osteoporosis Patients After Long-Term Bisphosphonate Treatment Report of a Task Force* of the American Society for Bone and Mineral Research Robert A. Adler, MD Task Force Co-Chairs Ghada El-Hajj
More informationNAMS Practice Pearl. Use of Drug Holidays in Women Taking Bisphosphonates. Released April 1, 2013
NAMS Practice Pearl Use of Drug Holidays in Women Taking Bisphosphonates Released April 1, 2013 Dima L. Diab, MD 1, and Nelson B. Watts, MD 2 ( 1 Cincinnati VA Medical Center, Cincinnati, OH, 2 Mercy Health
More informationA Review of Bone Health Issues in Oncology
A Review of Bone Health Issues in Oncology David L. Kendler MD FRCPC CCD Professor of Medicine (Endocrinology) University of British Columbia Vancouver Canada Disclosures David Kendler has received research
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationAN OVERVIEW of TREATMENT: WHO and WHEN to TREAT
AN OVERVIEW of TREATMENT: WHO and WHEN to TREAT Dolores Shoback, MD Professor of Medicine, UCSF San Francisco VA Medical Center July 16, 21 ~ QUESTIONS ~ Who should receive therapy to prevent fractures?
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationOsteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital
Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationHow long to treat? Disclosure. What is the real problem? Conclusions
Disclosure How long to treat? 11 th Annual Update on Osteoporosis and Skeletal Health Institutional Grant / Research Support Amgen, Eli Lilly, Merck Consulting / Speaking Amgen, Eli Lilly, Merck, Radius
More informationFRAX assessment. The patient. The patient. Which drug? UK NOGG Guidance 3/22/17. Safety issues with osteoporosis treatments
The patient Safety issues with osteoporosis treatments 78 year-old lady, retired dentist, active. Family history of osteoporosis (mother, younger sister). Humerus fracture 3 months ago. Type 2 diabetes
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationOsteoporosis TreatmentUpdate November 2018
Osteoporosis TreatmentUpdate November 2018 Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures Opinions are those of the speaker
More informationFracture=Bone Attack:
Fracture=Bone Attack: Linking Hip Fractures to Osteoporosis Care Angela M. Cheung, MD, PhD, FRCPC Professor of Medicine, University of Toronto Potential Conflicts of Interests Industry Grants (to UHN)
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationHot Topics in Osteoporosis and Fracture Prevention
Hot Topics in Osteoporosis and Fracture Prevention Sid Feldman, MD CCFP (COE) FCFP Sandra Kim, MD, FRCPC November 15, 2018 Family Medicine Forum, Toronto Faculty/Presenter Disclosure Faculty: Sid Feldman
More informationAACE. Osteoporosis Treatment: Then and Now
AACE 25 th Annual Scientific and Clinical Congress Osteoporosis Treatment: Then and Now Orlando, FL May 28, 2016 Michael R. McClung, MD Oregon Osteoporosis Center Portland, Oregon, USA Disclosures I am
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationAtypical Femoral Fractures With Long Term Bisphosphonates Use
Atypical Femoral Fractures With Long Term Bisphosphonates Use There has been an increase in the number of atypical femoral fractures in pa4ents on long term bisphosphonate therapy (e.g Fosamax) Accordingly
More informationNew Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence
New Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence John P. Bilezikian, MD, PhD(hon), MACE Silberberg Professor of Medicine Vice-Chair for International
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information.
4 4:45 pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationAACE. Orlando Drug Holidays. Disclosures. Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health
AACE Orlando 2016 Drug Holidays Disclosures Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health Scientific grants: Alexion, Amgen, Immunodiagnostics, Lilly, Merck, Regeneron, Radius Health, Roche
More informationAtypical Femoral Fractures Insights and Enigmas
Atypical Femoral Fractures Insights and Enigmas Madhu Mehta, M.D. Clinical Asst. Prof. of Medicine Department of Immunology/Rheumatology The Ohio State University Abreviations used TFF- Typical femoral
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationDisclosures. Bisphosphonate Treatment for Osteoporosis: Do the Benefits Outweigh the Risks? Risks vs Benefits. Bisphosphonates: Benefits and Risks
Bisphosphonate Treatment for steoporosis: Do the Benefits utweigh the Risks? 37 th Annual Advances in Internal Medicine May 18 and June 22, 29 hsponsored resentations Disclosures Eli Lilly & Company, GlaxoSmithKline,
More informationReducing the Risk of Fracture in Postmenopausal Women: Guidance for Family Physicians. Please complete the preassessment before the session starts.
Reducing the Risk of Fracture in Postmenopausal Women: Guidance for Family Physicians Please complete the preassessment before the session starts. Sponsorship and Support This educational activity is jointly
More informationOsteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus
Osteoporosis: current treatment and future prospects Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus Disclosures Consultancy and speaking fees for Gilead, related to development
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationHow to treat osteoporosis With what and for how long?
How to treat osteoporosis With what and for how long? Professor Neil Gittoes Consultant Endocrinologist & Honorary Professor Where will we be going? Drug therapies Current Indications Contraindications/unmet
More information11/4/2018. Osteoporosis Update. ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East. No disclosures.
Osteoporosis Update ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East No disclosures. 1 Goals Review screening recommendations and workup of secondary causes
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationOsteoporosis Management in Older Adults
Osteoporosis Management in Older Adults Angela M Cheung, MD, PhD, FRCPC, CCD Professor of Medicine, University of Toronto Disclosures Relationship with Commercial Entities: Honoraria from: Amgen, Eli Lilly,
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationACP Colorado-Evidence Based Management of Osteoporosis
ACP Colorado-Evidence Based Management of Osteoporosis Micol S. Rothman, MD Associate Professor of Medicine and Radiology Clinical Director Metabolic Bone Program University of Colorado School of Medicine
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 ACTONEL 5 mg, film-coated tablet B/14 (CIP code: 354 362-3) ACTONEL 30 mg, film-coated tablet B/28 (CIP
More informationBisphosphonate treatment break
Bulletin 110 December 2015 Bisphosphonate treatment break Bisphosphonates have been widely used in the treatment of osteoporosis with robust data demonstrating efficacy in fracture risk reduction over
More informationWho cares about fractures! is more important. October 3, 2014 CSIM Workshop Brian Wirzba, MD, FRCPC, FACP Clinical Professor Grey Nuns Hospital
Isn t Osteoporosis just a T Score less than 2.5?? Who cares about fractures! is more important. Why do I need to know this? October 3, 2014 CSIM Workshop Brian Wirzba, MD, FRCPC, FACP Clinical Professor
More informationBone Health Update Susan L. Greenspan, MD Professor of Medicine University of Pittsburgh
Bone Health Update 2018 Susan L. Greenspan, MD Professor of Medicine University of Pittsburgh The Problem 50% women and 20% of men have an osteoporotic fracture after age 50 2 million fractures annually
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationUpcoming Agents for Osteoporosis
Upcoming Agents for Osteoporosis May 5, 2017 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Professorial Fellow, Institute of Health and Ageing Australian Catholic
More informationOsteoporosis Update. Case 2. Case 1: Monday morning, 8:15
Osteoporosis Update Laura E. Ryan, MD Assistant Director for Special Programs Center for Women s Health Clinical Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio
More informationCurrent and Emerging Approaches for Osteoporosis
Current and Emerging Approaches for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures What s New in Osteoporosis
More informationConflict of Interest Jonathan D. Adachi
Conflict of Interest Jonathan D. Adachi Consultant/Speaker Actavis Amgen Eli Lilly Merck Clinical Trials Amgen Eli Lilly Merck Novartis Stock None to declare Current Controversies In Osteoporosis Provided
More informationPage 1. Osteoporosis Warm-Up: Which of the Following is True? Diagnosis and Treatment of Osteoporosis: What is New in What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What is New in 2017 Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationPage 1. Current and Emerging Strategies for Osteoporosis. Osteoporosis Warm-Up: Which of the Following is True?
Current and Emerging Strategies for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis Warm-Up:
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More information2016 AACE/ACE POSTMENOPAUSAL OSTEOPOROSIS GUIDELINES: Practical Applications. Outline. The Process. Osteoporosis Diagnosis NEW CLINICAL DEFINITION
2016 AACE/ACE POSTMENOPAUSAL OSTEOPOROSIS GUIDELINES: Practical Applications Steven M. Petak MD, JD, MACE, FACP Associate Clinical Professor Weill-Cornell Medical College Division Head and Chief of Endocrinology
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationTymlos (abaloparatide)
Tymlos (abaloparatide) Policy Number: 5.01.638 Last Review: 11/2018 Origination: 10/2017 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Tymlos
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. INJECTABLE OSTEOPOSIS AGENTS SUBJECT Pharmacologic Agents: Bisphosphonates: Boniva IV (ibandronate) Reclast (zoledronic
More informationOsteoporosis for the PCP and consultant COPYRIGHT. Harold Rosen, MD Director- Osteoporosis Prevention and Treatment Center
Osteoporosis for the PCP and consultant Harold Rosen, MD Director- Osteoporosis Prevention and Treatment Center Beth Israel Deaconess Medical Center Potential conflicts of interest None GOALS When to screen/treat?
More informationHot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis Aromatase Inhibitor-Induced Bone Loss in Early Breast Cancer Rachel Pessah-Pollack, M.D., F.A.C.E. Mount Sinai School
More informationBone Health for Women: Current Research, Initiatives and Recommendations
Page 1 BONE HEALTH FOR WOMEN: CURRENT RESEARCH, INITIATIVES AND RECOMMENDATIONS Dr. Melissa Kagarise This program has been brought to you by PharmCon PharmCon is accredited by the Accreditation Council
More informationOsteoporosis Update. UNM Continuum of Care Project March 24, E. Michael Lewiecki, MD
Osteoporosis Update UNM Continuum of Care Project March 24, 2017 E. Michael Lewiecki, MD New Mexico Clinical Research & Osteoporosis Center University of New Mexico School of Medicine Albuquerque, NM Disclosure
More information